Could a narcolepsy drug lift depression? phase 3 trial results are in

NCT ID NCT06360419

Completed Symptom relief Sponsor: Axsome Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 23 times

Summary

This Phase 3 trial tested whether solriamfetol, a drug already used for sleep disorders, can safely improve mood in adults with major depression. 346 participants received either the drug or a placebo. Researchers measured depression symptoms and side effects to see if this approach offers a new treatment option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Research Site

Little Rock, Arkansas, 72211, United States
Clinical Research Site

Bellflower, California, 90706, United States
Clinical Research Site

Encino, California, 91316, United States
Clinical Research Site

Lemon Grove, California, 91945, United States
Clinical Research Site

Los Angeles, California, 90015, United States
Clinical Research Site

Montclair, California, 91763, United States
Clinical Research Site

Oceanside, California, 92056, United States
Clinical Research Site

Redlands, California, 92374, United States
Clinical Research Site

Riverside, California, 92506, United States
Clinical Research Site

Sherman Oaks, California, 91403, United States
Clinical Research Site

Torrance, California, 90501, United States
Clinical Research Site

Upland, California, 91786, United States
Clinical Research Site

Walnut Creek, California, 94596, United States
Clinical Research Site

Cromwell, Connecticut, 06416, United States
Clinical Research Site

Brandon, Florida, 33511, United States
Clinical Research Site

Hialeah, Florida, 33012, United States
Clinical Research Site

Jacksonville, Florida, 32256, United States
Clinical Research Site

Orlando, Florida, 32801, United States
Clinical Research Site

Orlando, Florida, 32806, United States
Clinical Research Site

Orlando, Florida, 32807, United States
Clinical Research Site

Chicago, Illinois, 60634, United States
Clinical Research Site

Overland Park, Kansas, 66210, United States
Clinical Research Site

New Orleans, Louisiana, 70115, United States
Clinical Research Site

Boston, Massachusetts, 02131, United States
Clinical Research Site

Saint Charles, Missouri, 63304, United States
Clinical Research Site

Las Vegas, Nevada, 89102, United States
Clinical Research Site

Brooklyn, New York, 11235, United States
Clinical Research Site

Rochester, New York, 14609, United States
Clinical Research Site

Staten Island, New York, 10314, United States
Clinical Research Site

Hickory, North Carolina, 28601, United States
Clinical Research Site

Cincinnati, Ohio, 45215, United States
Clinical Research Site

Oklahoma City, Oklahoma, 73116, United States
Clinical Research Site

Media, Pennsylvania, 19063, United States
Clinical Research Site

Philadelphia, Pennsylvania, 19104, United States
Clinical Research Site

Memphis, Tennessee, 38119, United States
Clinical Research Site

Austin, Texas, 78737, United States
Clinical Research Site

Dallas, Texas, 75231, United States
Clinical Research Site

Friendswood, Texas, 77546, United States
Clinical Research Site

Wichita Falls, Texas, 76309, United States
Clinical Research Site

Everett, Washington, 98201, United States

Conditions

Explore the condition pages connected to this study.

MAJOR DEPRESSIVE DISORDER